Remdesivir Potentially Most Effective For Coronavirus: China Investigator
Executive Summary
Although AbbVie’s Kaletra has shown promising efficacy in COVID-19 patients, Gilead’s remdesivir has stronger antiviral activity, says one Chinese investigator leading studies in the coronavirus outbreak epicenter Wuhan.
You may also be interested in...
Gilead’s Major Challenge Is Sustainable Model For Remdesivir
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
What Is Behind China's 'Zero-COVID'? Money-Making Machines And Business Interest Chains
One well-connected individual registered as many as 35 nucleic testing firms within just a few months, all of which are strategically located in the Chinese cities that have seen some of the worst COVID-19 flareups. Meanwhile, regulators have halted the IPOs of 13 companies.